Gilead Sciences, Inc.

Gilead

GILD · NASDAQ

Healthcare

Catalog as of September 15, 2026. Not a live market feed.

Fiscal Year: 2025
Revenue: $29.4B
Assets: $59B
SEC filing: DEF 14A
Filed: March 20, 2026

Executive Compensation

Compensation reported for Gilead’s named executive officers, including salary, stock awards, incentive compensation, other compensation, and total compensation.

Named executive officer compensation
Executive	Position	Salary	Stock Awards	Incentives	Option Awards	Other	Reported total
Daniel P. O’Day	Chairman And Chief Executive Officer	$1,795,192	$15,238,402	$4,848,120	$4,500,060	$2,055,424	$28,437,198
Dietmar Berger	M.D., Ph.D. Chief Medical Officer	$969,231	$6,999,758	$4,603,594	$1,000,043	$350,252	$13,922,878
Johanna Mercier	Chief Commercial And Corporate Affairs Officer	$1,182,269	$4,564,517	$2,150,901	$1,299,976	$102,980	$9,300,643
Andrew D. Dickinson	Chief Financial Officer	$1,116,654	$4,321,741	$1,956,266	$1,299,976	$70,979	$8,765,616
Deborah H. Telman	Former Executive Vice President, Corporate Affairs And General Counsel	$977,334	$3,071,792	$0	$900,065	$55,478	$5,004,669

Daniel P. O’Day
Chairman And Chief Executive Officer
$28.4M
Reported total
Salary
$1,795,192
Stock awards
$15,238,402
Incentives
$4,848,120
Option awards
$4,500,060
Other
$2,055,424
Dietmar Berger
M.D., Ph.D. Chief Medical Officer
$13.9M
Reported total
Salary
$969,231
Stock awards
$6,999,758
Incentives
$4,603,594
Option awards
$1,000,043
Other
$350,252
Johanna Mercier
Chief Commercial And Corporate Affairs Officer
$9.3M
Reported total
Salary
$1,182,269
Stock awards
$4,564,517
Incentives
$2,150,901
Option awards
$1,299,976
Other
$102,980
Andrew D. Dickinson
Chief Financial Officer
$8.8M
Reported total
Salary
$1,116,654
Stock awards
$4,321,741
Incentives
$1,956,266
Option awards
$1,299,976
Other
$70,979
Deborah H. Telman
Former Executive Vice President, Corporate Affairs And General Counsel
$5M
Reported total
Salary
$977,334
Stock awards
$3,071,792
Incentives
$0
Option awards
$900,065
Other
$55,478

Daniel P. O’Day

Chairman And Chief Executive Officer

$28.4M

Reported total · FY2025 · SCT Total as filed

Source: DEF 14A Summary Compensation Table, filed March 20, 2026.

Salary: $1.8M
Stock Awards: $15.2M
Option Awards: $4.5M
Incentives: $4.8M
Other: $2.1M

Historical Compensation

Daniel P. O’Day total compensation, fiscal years 2023–2025.

Year-by-year total compensation
Fiscal Year	Salary	Stock Awards	Total Compensation
2025	$1,795,192	$15,238,402	$28,437,198
2024	$1,771,201	$12,426,816	$23,689,392
2023	$1,740,962	$11,865,090	$22,607,690

Named Executive Officers

Daniel P. O’Day

Chairman And Chief Executive Officer

Gilead · GILD

$28.4M

FY 2025 · DEF 14A

Andrew D. Dickinson

Chief Financial Officer

Gilead · GILD

$8.8M

FY 2025 · DEF 14A

Johanna Mercier

Chief Commercial And Corporate Affairs Officer

Gilead · GILD

$9.3M

FY 2025 · DEF 14A

Dietmar Berger

M.D., Ph.D. Chief Medical Officer

Gilead · GILD

$13.9M

FY 2025 · DEF 14A

Deborah H. Telman

Former Executive Vice President, Corporate Affairs And General Counsel

Gilead · GILD

$5M

FY 2025 · DEF 14A

Source information

Company: Gilead Sciences, Inc.
Ticker: GILD · NASDAQ
Filing type: DEF 14A
Fiscal year: 2025
Filing date: March 20, 2026
SEC accession number: 0001308179-26-000106

Source: U.S. Securities and Exchange Commission, DEF 14A Summary Compensation Table. View SEC filing

Related Companies

Johnson & Johnson

JNJ · NYSE

Joaquin Duato

Chairman/CEO

$32.8M

FY 2025 reported total

View company →

UnitedHealth

UnitedHealth Group Incorporated

UNH · NYSE

Stephen Hemsley

Chief Executive Officer

$60.9M

FY 2025 reported total

View company →

AbbVie

AbbVie Inc.

ABBV · NYSE

Robert A. Michael

Chairman Of The Board And Chief Executive Officer

$32.5M

FY 2025 reported total

View company →

Abbott

Abbott Laboratories

ABT · NYSE

Robert B. Ford

Chairman Of The Board And Chief Executive Officer

$24.2M

FY 2025 reported total

View company →